Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.

The diuretic effects of torasemide and of furosemide were compared in a double blind cross-over study in 13 patients with stable chronic heart failure. Single doses of 10 mg and 20 mg of torasemide and of 40 mg of furosemide were given orally, in a randomized order on 3 consecutive days. In addition, a placebo was administered on the day preceding the 3 active drug treatment days to obtain control data. Each experimental day was divided into three urine collection periods - 0 to 4 h, 4 to 12 h and 12 to 24 h. Urine output, ion excretion and clearance were measured during each of the 3 periods as well as for the 24-h period. Torasemide 20 mg was distinctly more active in each of the 3 collection periods and in the 24-h period than furosemide 40 mg, whereas no significant difference was found between furosemide 40 mg and torasemide 10 mg for most of the experimental data. From 0 to 4 h, both torasemide and furosemide significantly increased the urinary flow rate and the urinary excretion of sodium, chloride and calcium, while they decreased the urinary osmolality when compared to placebo. All the effects persisted in the 4 to 12 h period after torasemide 20 mg in contrast to furosemide, whose effects were limited to the 0 to 4 h period. In the third period (12-24 h), the urine volume fell below the placebo value after furosemide but not torasemide, and only torasemide 20 mg was followed by a persistent decrease in the urine osmolality.(ABSTRACT TRUNCATED AT 250 WORDS)

[Use of injectable amiodarone in patients with chronic respiratory insufficiency]. / Utilisation de l'amiodarone injectable chez des patients insuffisants respiratoires chroniques.

Intravenous amiodarone (5 mg/kg) was administered to 10 patients with chronic obstructive airways disease, hypercapnia and hypoxia, and pulmonary hypertension. Respiratory function tests, arterial blood gases, ECG, blood pressure and subjective tolerance were monitored. Subjective tolerance was excellent. The parameters investigated showed no significant changes either biologically or statistically, excepting a slowing of the cardiac rhythm. The authors conclude that amiodarone has no undesirable cardiopulmonary side effects.